These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18762671)

  • 21. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
    Zeymer U; Tebbe U; Weber M; Vohringer HF; Jaksch R; Bischoff KO; Toepel W; Marsalek P; Horn S; Neuhaus KL;
    J Invasive Cardiol; 2003 Jul; 15(7):385-9. PubMed ID: 12840235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.
    Velianou JL; Al-Suwaidi J; Mathew V
    Am J Cardiovasc Drugs; 2002; 2(5):315-22. PubMed ID: 14727961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.
    De Luca G; Suryapranata H; Grimaldi R; Chiariello M
    QJM; 2005 Sep; 98(9):633-41. PubMed ID: 16040669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA; Lincoff AM
    Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
    Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
    Nikolsky E; Aymong ED; Halkin A; Grines CL; Cox DA; Garcia E; Mehran R; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Cohen DA; Negoita M; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2004 Aug; 44(3):547-53. PubMed ID: 15358018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Pellizzon GG; Grines CL; Cox DA; Stuckey T; Tcheng JE; Garcia E; Guagliumi G; Turco M; Lansky AJ; Griffin JJ; Cohen DJ; Aymong E; Mehran R; O'Neill WW; Stone GW
    J Am Coll Cardiol; 2004 Apr; 43(8):1368-74. PubMed ID: 15093869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
    Antoniucci D; Migliorini A; Parodi G; Valenti R; Rodriguez A; Hempel A; Memisha G; Santoro GM
    Circulation; 2004 Apr; 109(14):1704-6. PubMed ID: 15066943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting.
    Ndrepepa G; Kastrati A; Neumann FJ; Schmitt C; Mehilli J; Schömig A
    Eur Heart J; 2004 Sep; 25(18):1635-40. PubMed ID: 15351163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
    Topol EJ; Lincoff AM; Kereiakes DJ; Kleiman NS; Cohen EA; Ferguson JJ; Tcheng JE; Sapp S; Califf RM
    Am J Med; 2002 Jul; 113(1):1-6. PubMed ID: 12106616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
    Kandzari DE; Tcheng JE; Cohen DJ; Bakhai A; Grines CL; Cox DA; Effron M; Stuckey T; Griffin JJ; Turco M; Carroll JD; Fahy M; Mehran R; Stone GW;
    Am J Cardiol; 2003 Oct; 92(7):779-84. PubMed ID: 14516875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.